|

To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer

RECRUITINGN/ASponsored by Yong Wha Moon
Actively Recruiting
PhaseN/A
SponsorYong Wha Moon
Started2025-04-01
Est. completion2026-12-31
Eligibility
Age20 Years+
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07651124

Summary

The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer. Participants undergo the following process: There must be a cancerous lesion available for biopsy or surgery, and enhanced tumor-infiltrating lymphocytes are cultured from ovarian cancer tissue collected from the subject. These are processed into human cells for administration and injected into the subject.

Eligibility

Age: 20 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Recurrent ovarian cancer
* There is a cancerous lesion that can be removed by biopsy or surgery.

Exclusion Criteria:

* Patient with immunodeficiency or autoimmune diseases that may be exacerbated by immunotherapy
* Patient deemed unsuitable by the principal investigator

Conditions2

CancerRecurrent Ovarian Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.